Altamira Therapeutics (CYTOF) Stock Statistics & Valuation Metrics

Altamira Therapeutics has a market cap or net worth of $443.21K. The enterprise value is $1.14M.

Altamira Therapeutics has 5,715,472 shares outstanding. The number of shares has decreased by -2.65% in one year.

Altamira Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Altamira Therapeutics is ―. Altamira Therapeutics’s PEG ratio is ―.

In the last 12 months, Altamira Therapeutics had revenue of 0.00 and earned -7.27M in profits. Earnings per share was -14.81.

In the last 12 months, operating cash flow was -10.81M and capital expenditures 0.00, giving a free cash flow of -10.81M billion.

Altamira Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Altamira Therapeutics upcoming earnings date is Sep 9, 2026, Before Open (Confirmed).

Altamira Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Altamira Therapeutics has paid 0.00 in taxes.

Altamira Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Altamira Therapeutics has $49.57K in cash and marketable securities with $3.47M in debt, giving a net cash position of -$3.42M billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Altamira Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―